Skip to main content
Clinical Trials/DRKS00032481
DRKS00032481
Recruiting
Not Applicable

Investigation of the gut microbiome in patients with head and neck cancer (HNSCC) and analysis of the prognostic potential of response and tolerability of PD-1, PDL-1 immune checkpoint inhibitors in head and neck cancer

ehrstuhl für Hals-Nasen-Ohrenheilkunde Universität Witten/Herdecke0 sites50 target enrollmentSeptember 4, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
head and neck carcinoma
Sponsor
ehrstuhl für Hals-Nasen-Ohrenheilkunde Universität Witten/Herdecke
Enrollment
50
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 4, 2023
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
ehrstuhl für Hals-Nasen-Ohrenheilkunde Universität Witten/Herdecke

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed head and neck carcinoma for which immune checkpoint inhibitor therapy (PD\-1, PD\-L1\) is planned as part of treatment

Exclusion Criteria

  • Age under 18, lack of capacity to consent, and lack of patient consent

Outcomes

Primary Outcomes

Not specified

Similar Trials